GlassScriptPhysician profile
Nancy L Verhoff
NPI 1275535882
$2,149.53
in general payments reported to CMS, 2019-2025
25 companies · $166 in 2025
The $166 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $402 · 2020: $292 · 2021: $269 · 2022: $450 · 2023: $321 · 2024: $248 · 2025: $166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $735.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $735.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $721.94 | 2022-2025 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $213.64 | 2019-2023 | Farxiga |
| Pfizer INC. | $176.02 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $143.07 | 2019-2022 | |
| Astellas Pharma US INC | $116.60 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $73.97 | 2025 | Caplyta |
| Glaxosmithkline, LLC. | $71.65 | 2019-2023 | Trelegy Ellipta |
| Amarin Pharma, INC. | $70.17 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $67.55 | 2021-2023 | |
| Novo Nordisk INC | $61.86 | 2019-2020 | |
| Exact Sciences Corporation | $52.17 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.70 | 2019 | |
| Dexcom, INC. | $49.79 | 2022-2023 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $43.08 | 2022 | |
| Lilly USA, LLC | $34.57 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $30.45 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $27.19 | 2024-2025 | Voquezna |
| Sanofi Pasteur INC. | $23.85 | 2019 | |
| Amgen INC. | $23.45 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.53 | 2019 | |
| Sanofi-Aventis U.S. LLC | $20.69 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.05 | 2022 | |
| Novartis Pharmaceuticals Corporation | $13.74 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $12.91 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $11.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Verhoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.